Versant Capital Management, Inc Phathom Pharmaceuticals, Inc. Transaction History
Versant Capital Management, Inc
- $578 Million
- Q1 2025
A detailed history of Versant Capital Management, Inc transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 197 shares of PHAT stock, worth $809. This represents 0.0% of its overall portfolio holdings.
Number of Shares
197Holding current value
$809% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
158Shares Held
68.4MCall Options Held
52.3KPut Options Held
635K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$41.5 Million4.92% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$30.7 Million12.73% of portfolio
-
Jennison Associates LLC7.06MShares$29 Million0.04% of portfolio
-
Invesco Ltd. Atlanta, GA3.67MShares$15.1 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$14.4 Million28.4% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $161M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...